Company Profile

Industry Sector: Life Sciences Biotechnology

Company Overview: VBI is an emerging, venture-backed biotech company founded in 2004. We have developed novel 3D or Mini-tissue human bioassay platforms to accelerate drug discovery, preclinical and biomedical research.

VBI’s advanced technology allows rapid in vitro analysis of drug efficacy, toxicity and therapeutic endpoints – the major bottlenecks of current drug discovery pipeline. Thus, it is enormously valuable for providing critical ‘Go or No-go’ decisions prior to expensive clinical trials.

Target Market(s):
- Preclinical Drug Efficacy/Toxicity
- Personalized Medicine
- Functional Genomics
- Regenerative Medicine (Stem cells)

Key Value Drivers

Technology*: Patented 3D HuBiogel™ is employed to develop new in vitro human bioassay systems for real-time analysis of tumorigenesis, angiogenesis and liver toxicity. Successfully used to identify new drug candidates and for better prediction of drug activity/toxicity and therapy response in patients.

Competitive Advantage:
- Unlike 2D cell-based assays, 3D HuBiogel assays mimic in-vivo like biology.
- Mini-tissue assay models allow studies of both normal and disease states.
- High value utility in accelerating drug discovery & functional genomics.
- New ‘all-human’ bioassays useful across basic, preclinical & therapy arenas.


*Technology funded by the NIH/NCI and being commercialized under the NIH-CAP

Management

Leadership:
- Raj Singh, PhD: Founder, President and CEO
- Lee Martin, PhD: Sr. Director, Business Develop & Marketing
- Albert LoBuglio, MD: Oncologists & Emr. Director, UAB Cancer Center
- Larry Delucas, PhD, DSc: Professor & Director, CBSE, UAB

VC Members:
- Linda Powers, JD: Managing Dir., Toucan Capital, MD
- Larry Greer, DSD, MBA: Managing Dir., Greer Capital, AL

Scientific Advisors & Consultants:
- Norton Peet, PhD: International R&D Expert, Boston, MA
- Mina Bissell, PhD: Disting. Professor, Cancer Biology, LBNL, CA

Product Pipeline

<table>
<thead>
<tr>
<th>VBI Products</th>
<th>Status &amp; Plan</th>
<th>Time Line</th>
</tr>
</thead>
<tbody>
<tr>
<td>HuBiogel culture kits</td>
<td>Sales</td>
<td>2008</td>
</tr>
<tr>
<td>3D Bioassays</td>
<td>Contract services</td>
<td>2008</td>
</tr>
<tr>
<td>Mini-Tumor culture kits</td>
<td>End-users</td>
<td>2009</td>
</tr>
<tr>
<td>Preclinical DD tool</td>
<td>Validation by Big Pharma</td>
<td>2010</td>
</tr>
<tr>
<td>Patient Therapy Prediction</td>
<td>Validation plan for FDA review</td>
<td>2012</td>
</tr>
</tbody>
</table>